Vetter Combines Laboratory Portfolio into Single Site
The new 1800-m2 building houses more than 50 employees and features non-GMP laboratory space and a GMP analytical laboratory.
Vetter, a contract development and manufacturing organization based in Germany, announced on Jan. 30, 2020 that it has combined its development laboratories into one site located in Ravensburg, Germany.
The new 1800-m2 building houses more than 50 employees and features process development capabilities, functional and specification testing of packaging systems, and chemical-analytical, biochemical analysis, and particle characterization abilities, according to a company press release. The non-GMP laboratory space and the GMP analytical laboratory will also enable increased capacity and optimized workspaces.
The company decided to combine the labs to improve workflow and give employees the opportunity to share expertise, simplify information exchange, leverage synergies, and reinforce a positive work atmosphere, the release said. Customers will also benefit from the venture through daily support in complex development projects.
“Our customers are excited and impressed with the new and modern development laboratories and their increased capacity. Now they can follow a complete development process and its individual steps, since it proceeds throughout the labs, all within the same building,” said Dr. Claus Feussner, senior vice-president of Development Services, Vetter, in the press release. “Expansion will continue within the building throughout the year and includes more lab space and the provision of additional innovative analytical equipment and lyophilizer capacity.
Source: Vetter
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
